Multicenter retrospective study of 132 patients with unresectable small bowel adenocarcinoma treated with chemotherapy

Oncologist

Volumn 17, Issue 9, 2012, Pages 1163-1170

  Tsushima, Takahiro ^a   Taguri, Masataka ^b   Honma, Yoshitaka ^c   Takahashi, Hideaki ^d   Ueda, Shinya ^e   Nishina, Tomohiro ^f   Kawai, Hiroki ^g   Kato, Shunsuke ^h   Suenaga, Mitsukuni ⁱ   Tamura, Fumio ^j   Morita, Satoshi ^b   Boku, Narikazu ^a,k  

^a SHIZUOKA CANCER CENTER   (Japan)

^b YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^e KINDAI UNIVERSITY HOSPITAL   (Japan)

^f NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^g AICHI CANCER CENTER HOSPITAL   (Japan)

^h TOHOKU UNIVERSITY HOSPITAL   (Japan)

ⁱ CANCER INSTITUTE HOSPITAL   (Japan)

^j National Hospital Organization   (Japan)

^k ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Adenocarcinoma; Chemotherapy; Prognostic factor; Small bowel cancer

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; OXALIPLATIN; PACLITAXEL; UFT;

ADULT; AGED; CANCER CHEMOTHERAPY; CLINICAL TRIAL (TOPIC); CONTINUOUS INFUSION; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GASTROINTESTINAL CARCINOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; RETROSPECTIVE STUDY; REVIEW;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTESTINAL NEOPLASMS; INTESTINE, SMALL; JAPAN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ORGANOPLATINUM COMPOUNDS; PYRIMIDINES; RETROSPECTIVE STUDIES;

EID: 84866558638     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0079     Document Type: Review

References (36)

1. Siegel R, Ward E, Bradley O et al. Cancer statistics, 2011: The impact of eliminating socioeconomic and ra-cial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212-236.
2. Weiss NS, Yang CP. Incidence of histologic types of can-cer of thes mall intestine. J Natl Cancer Inst 1987;78:653.
3. Garcia Marcilla JA, Sanchez Bueno F, Aguilar J et al. Primary small bowel malignant tumors. Eur J Surg Oncol 1994;20:630.
4. DiSario JA, Burt RW, Vargas H et al. Small bowel cancer: Epidemiological and clinical characteristics from a population-based registry. Am J Gastroenterol 1994;89:699.
5. Hatzaras I, Palesty JA, Abir F et al. Small-bowel tu-mors:Epidemiologicandclinicalcharacteristicsof1260 cases from the Connecticut tumor registry. Arch Surg 2007;142:229.
6. Lepage C, Bouvier A-B, Manfredi S et al. Incidence and management of primary malignant small bowel can-cers: A well-defined French population study. Am J Gas-troenterol 2006;101:2826.
7. Talamoni MS, Goetz LH, Rao S et al. Primary cancers of the small bowel: Analysis of prognostic factors and results of surgical management. Arch Surg 2002; 137:564-570.
8. Bilimoria KY, Bentrem DJ, Wayne JD et al. Small bowel cancer in the United States: Changes in epidemi-ology, treatment, and survival over the last 20 years. Ann Surg 2009;249(1):63.
9. Dabaja BS, Suki D, Pro B et al. Adenocarcinoma of the small bowel: Presentation, prognostic factors, and outcome of 217 patients. Cancer 2004;101(3):518-526.
10. Halfdanarson T, McWilliams RR, Donohue JH et al. A single-institution experience with 491 cases of small bowel adenocarcinoma. Am J Surg 2010;199:797-803.
11. Fishman PN, Pond GR, Moore MJ et al. Natural history and chemotherapy effectiveness for advanced adenocarcinoma of the small bowel: A retrospective review of 113 cases. Am J Clin Oncol 2006;29:225-231.
12. Czaykowski P, Hui D. Chemotherapy in small bowel adenocarcinoma:10-year experienceoftheBritishColum-bia Cancer Agency. Clin Oncol 2007;19:143-149.
13. Ouriel K, Adams JT. Adenocarcinoma of the small intestine. Am J Surg 1984;147:66-71.
14. Gibson MK, Holcroft CA, Kvols LK et al. Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma. The Oncologist 2005;10:132-137.
15. Ono M, Shirao K, Takashima A et al. Combination chemotherapy with cisplatin and irinotecan in patients withadenocarcinomaofthesmallintestine. GastricCancer 2008;11:201-205.
16. Locher C, Malka D, Boige V et al. Combination chemotherapy in advanced small bowel adenocarci-noma. Oncology 2005;69:290-294.
17. Crawley C, Ross P, Hill A et al. The Royal Marsden experience of small bowel adenocarcinoma treated with protracted venous infusion 5-fluorouracil. British J Can-cer 1998;78:508-510.
18. Suenaga M, Mizunuma N, Chin K et al. Chemo-therapy for small-bowel adenocarcinoma at a single in-stitution. Surg Today 2009;39:27-31.
19. Jigyasu D, Bedikian AY, Strohlein JR. Chemother-apy for primary adenocarcinoma of the small bowel. Cancer 1984;53:23-25.
20. Goetz MP, Erlichman C, Windebank AJ et al. Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, fluorouracil, and leucovorin in patients with solid tumors. J Clin Oncol 2003;21:3761-3769.
21. Overman MJ, Kopetz S, Wen S et al. Chemother-apy with 5-fluorouracil and a platinum compound im-proves outcomes in metastatic small bowel adenocarcinoma. Cancer 2008;113:2038-2045.
22. Zaanan A, Costes L, Gauthier M et al. Chemother-apy of advanced small-bowel adenocarcinoma: A multi-center AGEO study. Ann Oncol 2010;21:1786-1793.
23. Overman MJ, Vardhachary GR, Kopetz S et al. Phase II study of capecitabine and oxaliplatin for ad-vanced adenocarcinoma of the small bowel and ampulla of Vater. J Clin Oncol 2009;27:2598-2603.
24. Kemeny N, Israel K, Neidzwiecki D e t al. Random-ized study of continuous infusion fluorouracil versus fluorouracil plus cisplatin in patients with metastatic colorectal cancer. J Clin Oncol 1990;8:313-318.
25. Hansen RM, Ryan L, Anderson T et al. Phase III study of bolus versus infusion fluorouracil with or with-out cisplatin in advanced colorectal cancer. J Natl Can-cer Inst 1996;88:668-674.
26. Lokich JJ, Ahlgren JD, Cantrell J et al. A prospec-tive randomized comparison of protracted infusional 5-fluorouracil with or without weekly bolus cisplatin in metastatic colorectal carcinoma. A Mid-Atrantic Oncol-ogy Program study. Cancer 1991;67:14-19.
27. Loehrer Sr PJ, Turner S, Kubilis P et al. Aprospec-tive randomized trial of fluorouracil versus fluorouracil plus cisplatin in the treatment of metastatic colorectal cancer: A Hoosier Oncology Group Trial. J Clin Oncol 1988;6:642-648.
28. Overman MJ, Pozadzides J, Kopetz S et al. Immuno-phenotype and molecular characterization of adenocarcinoma of the small intestine. Br J Cancer 2010;102:144-150.
29. Haan JC, Buffart TE, Eijk PP et al. Small bowel adenocarcinoma copy number profiles are more closely related to colorectal than to gastric cancers. Ann Oncol 2012;23:367-374.
30. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus flu-orouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-914.
31. Douillard JY, Cunningham D, Roth AD et al. Iri-notecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lan-cet 2000;355:1041-1047.
32. Koo DH, Yun SC, Hong YS et al. Systemic che-motherapy for treatment of advanced small bowel ade-nocarcinoma with prognostic factor analysis: Retrospective study. BMC Cancer 2011;11:205.
33. Speranza G, Doroshow JH, Kummar S. Adenocar-cinoma of the small bowel: Changes in the landscape? Curr Opin Oncal 2010;22:287-393.
34. Howe JR, Karnell LH, Menck HR et al. The Amer-ican College of Surgeons Commissionon Cancer and the American Cancer Society. Adenocarcinoma of the small bowel: Review of the National Cancer Data Base, 1985-1995. Cancer 1999;86:2693-2706.
35. Wu TJ, Yeh CN, Chao TC et al. Prognostic factors of primary small bowel adenocarcinoma:Univariate and multivariate analysis. World J Surg 2000;30:391-398.
36. Hong SH, Koh YH, Rho SY et al. Primaryadenocarci-noma of the small intestine: presentation, prognostic factors and clinical outcome. Jpn J Clin Oncol 2009;39:54-61.